FDA Panel Overwhelmingly Backs Approval Of Anti-Obesity Pill

SILVER SPRING, Md. (AP) — A panel of advisers to the Food and Drug Administration overwhelmingly backed approval for a highly anticipated anti-obesity pill from Vivus Inc., a drug which the FDA previously rejected due to safety concerns.

The FDA panel of outside physicians voted 20-2 in favor of the weight loss drug Qnexa, setting the stage for a potential comeback for a drug that has been plagued by side effects since it was first submitted to the agency in 2010.

A majority of panelists ultimately backed the drug due to its impressive weight loss results, with most patients reporting nearly 10 percent weight loss. But the group stressed the importance of confirming the drug’s safety, particularly its effects the heart, by tracking patients in a large, follow-up study. FDA’s decision is expected in April.

Top Content On CBSPhilly

More from Stephanie Stahl

One Comment

  1. misterlucky says:

    ………well, that’s enough dots…”outside physicians”..outside of what? Certainly not the circle of entrepreneuralism…the side effects from this catch-22 joke will keep the waiting rooms full till the spillover chokes ER…at least til some law firm in poontawket decides to fish for class action feeders: looking for those who took the dope to stimulate weight loss for their health’s sake, only to suffer or die from heart disease brought on or aggravated by the side effects…Hey!, run that story about how good wine is for the blood.

Comments are closed.

More From CBS Philly

Getaway Guide: Best Of The Jersey Cape Clams

Watch & Listen LIVE